Swiss National Bank boosted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 5.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 66,400 shares of the biopharmaceutical company’s stock after buying an additional 3,300 shares during the period. Swiss National Bank owned approximately 141,487.32% of Xencor worth $1,522,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the period. Legal & General Group Plc raised its holdings in Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the period. Principal Financial Group Inc. purchased a new stake in Xencor during the 3rd quarter valued at $201,000. Citadel Advisors LLC purchased a new stake in Xencor during the 2nd quarter valued at $224,000. Finally, Airain ltd raised its holdings in Xencor by 49.9% during the 2nd quarter. Airain ltd now owns 13,360 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 4,447 shares during the period. Institutional investors own 76.97% of the company’s stock.

In other Xencor news, major shareholder John S. Stafford III bought 24,653 shares of Xencor stock in a transaction on Wednesday, October 25th. The shares were acquired at an average price of $20.01 per share, for a total transaction of $493,306.53. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 3,400 shares of Xencor stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $19.89 per share, for a total transaction of $67,626.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 242,382 shares of company stock worth $4,795,353. Insiders own 4.03% of the company’s stock.

Shares of Xencor, Inc. (NASDAQ:XNCR) opened at $20.36 on Friday. Xencor, Inc. has a 52 week low of $18.55 and a 52 week high of $29.38.

Several analysts recently weighed in on the company. Canaccord Genuity restated a “buy” rating and set a $36.00 price target on shares of Xencor in a report on Tuesday, August 8th. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $30.25.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/swiss-national-bank-buys-3300-shares-of-xencor-inc-xncr/1727100.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.